Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000455
Status:
COMPLETED
Last Update Posted:
2011-06-20
First Post:
1999-11-02
Brief Title:
Naltrexone for Early Problem Drinkers
Sponsor:
UConn Health
Organization:
UConn Health
Study Overview
Official Title:
Targeted Naltrexone for Early Problem Drinkers
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Early problem drinkers are prevalent in the United States Recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence
Although naltrexone Revia has been approved for the treatment of alcohol dependence few pharmacotherapy studies have been undertaken with early problem drinkers This study is an 8-week trial of naltrexone versus placebo combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication A total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups Followup evaluations will be conducted at the end of treatment and again 3 6 and 12 months
Although naltrexone Revia has been approved for the treatment of alcohol dependence few pharmacotherapy studies have been undertaken with early problem drinkers This study is an 8-week trial of naltrexone versus placebo combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication A total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups Followup evaluations will be conducted at the end of treatment and again 3 6 and 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01AA011062 | NIH | None | httpsreporternihgovquickSearchR01AA011062 |